Skip to content
LATEST
Business

Marine Biomedical Secures FDA Clearance for PearlBone Graft with Orthocell Stake

Marine Biomedical has secured FDA clearance for its PearlBone graft, triggering potential commercialization efforts supported by a 12% equity stake held by…

Marine Biomedical Secures FDA Clearance for PearlBone Graft with Orthocell Stake

Marine Biomedical has received US Food and Drug Administration 510(k) clearance for its PearlBone bone graft substitute. This regulatory approval permits the product to be marketed within the United States for orthopedic, trauma, and reconstructive surgical applications.

Orthocell holds a 12% equity interest in Marine Biomedical following a $1.05 million investment. The agreement grants Orthocell a right of first refusal regarding global distribution rights for PearlBone and future product iterations.

Marine Biomedical

Orthocell intends to leverage its existing US commercial infrastructure and surgeon networks to facilitate the market entry of the biomaterial. The product utilizes nacre sourced from pearl shells, with manufacturing operations currently centralized in Western Australia.

This development represents a strategic expansion for Orthocell, aiming to integrate bone regeneration technology into its existing portfolio of nerve and tendon repair products. Marine Biomedical is currently finalizing manufacturing readiness and commercial partnership strategies ahead of the formal US launch.

More stories

Latest news